Madrigal exceeds target enrollment in phase 3 maestro nafld-1 trial

Madrigal pharmaceuticals exceeds target enrollment in phase 3 maestro nafld-1 trial.madrigal pharmaceuticals - completion of enrollment in maestro-nafld-1 will enable reporting of topline 52-week data by end of next year as planned.madrigal pharmaceuticals inc - intends to present selected data from ongoing open label arm by end of 2020.
MDGL Ratings Summary
MDGL Quant Ranking